These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38924340)

  • 41. Fatal acute graft-versus-host disease in Sézary Syndrome treated with Mogamulizumab and hematopoietic cell transplantation.
    Trotta GE; Ciangola G; Cerroni I; Mezzanotte V; Nunzi A; Anemona L; Savino L; De Angelis G; Mariotti B; Bonanni F; Meddi E; Zizzari A; Rapisarda VM; Mangione I; Bruno A; Cantonetti M; Venditti A; Cerretti R
    Curr Res Transl Med; 2024 Sep; 72(3):103452. PubMed ID: 38718540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
    Duvic M; Pinter-Brown LC; Foss FM; Sokol L; Jorgensen JL; Challagundla P; Dwyer KM; Zhang X; Kurman MR; Ballerini R; Liu L; Kim YH
    Blood; 2015 Mar; 125(12):1883-9. PubMed ID: 25605368
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
    Dugas-Breit S; Schulze HJ; Hallermann C
    J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients.
    de Masson A; Darbord D; Dobos G; Boisson M; Roelens M; Ram-Wolff C; Cassius C; Le Buanec H; de la Grange P; Jouenne F; Louveau B; Sadoux A; Bouaziz JD; Marie-Cardine A; Bagot M; Moins-Teisserenc H; Mourah S; Battistella M
    Blood; 2022 Mar; 139(12):1820-1832. PubMed ID: 34905599
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mogamulizumab and bexarotene are a promising association for the treatment of advanced cutaneous T-cell lymphomas: a case series.
    Teoli M; Mandel VD; Franceschini C; Saraceni PL; Cicini MP; Ardigò M
    Eur Rev Med Pharmacol Sci; 2022 Nov; 26(21):8118-8128. PubMed ID: 36394762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
    Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
    Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
    Fernández-Guarino M; Ortiz P; Gallardo F; Llamas-Velasco M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.
    Jawed SI; Busam K; Wang X; Horwitz S; Querfeld C
    JAMA Dermatol; 2014 Sep; 150(9):1021-3. PubMed ID: 25029560
    [No Abstract]   [Full Text] [Related]  

  • 49. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
    Jfri A; Smith JS; Larocca C
    J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
    [No Abstract]   [Full Text] [Related]  

  • 50. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
    Estève E; Bagot M; Joly P; Souteyrand P; Beylot-Barry M; Vaillant L; Delaunay M; Avril MF; Laroche L; Grange F; Thomine E; Wechsler J
    Arch Dermatol; 1999 Nov; 135(11):1349-53. PubMed ID: 10566833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
    del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
    Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclosporine in the treatment of cutaneous T cell lymphoma.
    Street ML; Muller SA; Pittelkow MR
    J Am Acad Dermatol; 1990 Dec; 23(6 Pt 1):1084-9. PubMed ID: 2273106
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study).
    Tzoumpa S; Ingen-Housz-Oro S; de Masson A; Pham-Ledard A; El Aarbaoui T; Dereure O; Quereux G; Faiz S; de Vicq de Cumptich M; Ram-Wolff C; Janela-Lapert R; Guenova E; Lheure C; Le Corre Y; Adamski H; Blanchard M; Bonnet N; Amatore F; Grange F; Troin L; Bagot M; Beylot-Barry M
    Br J Dermatol; 2024 Jun; 191(1):143-144. PubMed ID: 38660811
    [No Abstract]   [Full Text] [Related]  

  • 54. Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem.
    Larocca C; Kupper TS; LeBoeuf NR
    Clin Cancer Res; 2019 Dec; 25(24):7272-7274. PubMed ID: 31615932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.
    Dai J; Almazan TH; Hong EK; Khodadoust MS; Arai S; Weng WK; Kim YH
    JAMA Dermatol; 2018 Jun; 154(6):728-730. PubMed ID: 29800117
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
    Musiek ACM; Rieger KE; Bagot M; Choi JN; Fisher DC; Guitart J; Haun PL; Horwitz SM; Huen AO; Kwong BY; Lacouture ME; Noor SJ; Rook AH; Seminario-Vidal L; Vermeer MH; Kim YH
    Dermatol Ther (Heidelb); 2022 Jan; 12(1):29-40. PubMed ID: 34816383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
    Afifi S; Mohamed S; Zhao J; Foss F
    Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
    [No Abstract]   [Full Text] [Related]  

  • 58. Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma.
    Sentis HJ; Willemze R; Scheffer E
    J Am Acad Dermatol; 1986 Dec; 15(6):1217-26. PubMed ID: 2948972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
    Nevet MJ; Zuckerman T; Sahar D; Bergman R
    Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides.
    Wang J; Ram-Wolff C; Dobos G; Al Hage J; Grange F; Rivet J; Vignon-Pennamen MD; Moins-Teisserenc H; Boisson M; Moegle C; Sadoux A; Mourah S; Battistella M; Bagot M; de Masson A
    Br J Dermatol; 2022 Jul; 187(1):129-131. PubMed ID: 35083741
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.